
    
      Pancreatic cancer is a kind of cancer with poor prognosis. Nowadays, recommended treatment
      for late-stage or recurrent pancreatic cancer patients are fluorouracil based chemotherapy
      (such as FOLFIRINOX) and gemcitabine based chemotherapy. When these two chemo regimes are
      failed, however, there is no alternative options. With the improvement of immune therapy,
      anti-PD-1 antibody has became a promising anti-cancer drug. While it showed limited efficacy
      in pancreatic cancer. Stereotactic Body Radiotherapy (SBRT) has been a new method to locally
      treat metastatic cancer. And previous studies showed that SBRT may enhance the efficacy of
      immunotherapy. So this study is amed to evaluate the safety and efficacy of the combination
      of SBRT and anti-PD-1 antibody in late-stage or recurrent pancreatic caner who failed in
      second-line chemotherapy.
    
  